Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on November 18, 2025. The filing addresses Item 5.02 regarding the departure of a senior officer and the execution of a Transition and Release Agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material change is the formalization of the departure of Nicole LaBrosse, Senior Vice President and Chief Financial Officer. While a transition plan was previously disclosed, the Company and Ms. LaBrosse entered into a definitive Transition and Release Agreement on November 18, 2025. Ms. LaBrosse will continue to serve as CFO until the earliest of the hiring of a successor, March 30, 2026, or an earlier date determined by the Company.
Guidance, Outlook, and Management Commentary
The filing details the specific compensatory arrangements for Ms. LaBrosse's separation, which are contingent upon her compliance with the agreement and execution of a release of claims. Key terms include:
- 2025 Bonus: Eligible for the annual bonus at 120% of the target-level individual performance.
- Severance: A cash payment equal to her annual base salary plus, if separation occurs in 2026, a pro-rated 2026 annual bonus at target-level performance.
- Equity Vesting: If separation occurs prior to February 28, 2026, outstanding equity awards vesting solely on continued service that would have vested by that date will vest on the Separation Date.
- Option Exercise Period: An extension to exercise vested options to the shorter of one year following the Separation Date or the remaining term of the options.
- Change in Control: If a Change in Control occurs within one year of the Separation Date, all unvested options will vest upon consummation.
- Healthcare: Company coverage for COBRA continuation for one year following the Separation Date.
The filing states that the full agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2025.
Investor Verification Checklist
- Verify the exact "Separation Date" once the new CFO is hired or the March 30, 2026 deadline is reached.
- Review the full Transition and Release Agreement when filed as an exhibit to the 2025 Form 10-K for complete legal terms.
- Monitor the Company's announcement regarding the appointment of a new Chief Financial Officer.
- Confirm the impact of the CFO transition on the timing of the 2025 Form 10-K filing and financial reporting.